|
Orthologous residues
|
|
RANBP3 (human): S126‑p, RANBP3 iso2 (human): S126‑p, RANBP3 iso3 (human): S58‑p, RANBP3 (mouse): S58‑p, RANBP3 (rat): S58‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mass spectrometry, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
p90RSK (human)
|
pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme, phospho-antibody, siRNA inhibition of enzyme
|
|
|
KINASE
|
RSK2 (human)
|
pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme, phospho-antibody, siRNA inhibition of enzyme
|
|
|
KINASE
|
Akt1 (human)
|
pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme, phospho-antibody, siRNA inhibition of enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phorbol ester
|
|
|
|
increase
|
|
|
LY294002
|
phorbol ester
|
|
|
no effect upon treatment-induced increase
|
|
|
U0126
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
rapamycin
|
phorbol ester
|
|
|
no effect upon treatment-induced increase
|
|
|
insulin
|
|
|
|
increase
|
|
|
Akt-I-1
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
LY294002
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
U0126
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
U0126, LY294002
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
rapamycin
|
insulin
|
|
|
no effect upon treatment-induced increase
|
|
|
EGF
|
|
|
|
increase
|
|
|
LY294002
|
EGF
|
|
|
inhibit treatment-induced increase
|
|
|
U0126
|
EGF
|
|
|
inhibit treatment-induced increase
|
|
|
U0126, LY294002
|
EGF
|
|
|
inhibit treatment-induced increase
|
|
|
rapamycin
|
EGF
|
|
|
no effect upon treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
inhibition, intracellular localization, molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
RAN (human)
|
|
Induces
|
intracellular localization, activation
|
|
co-immunoprecipitation, chemical cross-linking
|
|
|
Comments:
inhibits RCC1 activity
|
